Oct 20 2026
First Access to Takeda Orexin Agonist for Narcolepsy in Japan and China
Posted at Oct 20 2026
h in News
h in News
Just announced from Takeda: Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
OSAKA, Japan and CAMBRIDGE, Massachusetts, October 15, 2026 – Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1.
Read the full release